Cardiac Sarcoidosis

Current Cardiology Reports

Volumn 16, Issue 8, 2014, Pages

  Zipse, Matthew M ^a,b   Sauer, William H ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Arrhythmia; Atrioventricular block; Cardiac sarcoidosis; Cardiomyopathy; Heart failure; Sudden cardiac death

Indexed keywords

EID: 84902940913     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0514-3     Document Type: Review

References (92)

1. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DLT, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine. 2004;83:315–34.
2. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9–21.
3. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivistö SM, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270:461–8.
4. Yazaki Y, Isobe M, Hiroe M, Morimoto S-I, Hiramitsu S, Nakano T, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol Elsevier. 2001;88:1006–10.
5. Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.
6. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med. 1997;336:1224–34.
7. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clin Chest Med. 1997;18:681–94.
8. Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130:29–32.
9. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204–11.
10. Tachibana T, Iwai K, Takemura T. Study on cause of death in the patients with sarcoidosis in Japan. Sarcoidosis Sigilim SRL. 1992;9:307–7.
11. Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278:455–69.
12. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170:1324–30.
13. Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by propionibacterium acnes. BioMed Res Int. 2013;2013:1–18.
14. Tchernev G, Ananiev J, Cardoso JC, Wollina U, Verma SB, Patterson JW, et al. Sarcoidosis and molecular mimicry—important etiopathogenetic aspects: current state and future directions. Wien Klin Wochenschr Springer. 2012;124:227–38.
15. Baughman RP, Lower EE, Bois du RM. Sarcoidosis. Lancet. 2003;361:1111–8.
16. Schürmann M, Lympany PA, Reichel P, Müller-Myhsok B, Wurm K, Schlaak M, et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med. 2000;162:861–4.
17. Doughan AR. Cardiac sarcoidosis. Heart. 2006;92:282–8.
18. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86–108.
19. Navaneethan SD, Venkatesh S, Shrivastava R, Mehta J, Israel R. Recurrent pleural and pericardial effusions due to sarcoidosis. PLoS Med. 2005;2:e63.
20. Sekhri V, Sanal S, DeLorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;4:546–54.
21. Schuller JL, Lowery CM, Zipse M, Aleong RG, Varosy PD, Weinberger HD, et al. Diagnostic utility of signal-averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:70–6.
22. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace. 2013;15:347–54. A multicenter retrospective review which represents the largest published cohort of cardiac sarcoidosis patients with ICDs.
23. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925–9. One of three 2012 studies of CS patients with ICDs. No primary prevention patients with normal LV and RV function received an appropriate therapy for VT.
24. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DLT, et al. Cardiac sarcoidosis. Medicine. 2004;83:315–34.
25. Schuller JL, Olson MD, Zipse MM, Schneider PM, Aleong RG, Wienberger HD, et al. Electrocardiographic characteristics in patients with pulmonary sarcoidosis indicating cardiac involvement. J Cardiovasc Electrophysiol. 2011;22:1243–8.
26. Yoshida Y, Morimoto S, Hiramitsu S, Tsuboi N, Hirayama H, Itoh T. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J. 1997;134:382–6.
27. Gozo EG, Cosnow I, Cohen HC, Okun L. The heart in sarcoidosis. Chest Am Coll Chest Phys. 1971;60:379–88.
28. Abeler V. Sarcoidosis of the cardiac conducting system. Am Heart J. 1979;97:701–7.
29. Ton K, Schulman S, Lima J, Tandri H. Cardiac Sarcoidosis Presenting as Sick Sinus Syndrome and Recurrent Ventricular Tachycardia. HRS 2014. 2014. pp. 1–1.
30. Zipse MM, Schuller JL, Katz DF, Steckman DA, Gonzalez JE, Sung RK, et al. Atrial Arrhythmias are Common and Arise from Diverse Mechanisms in Patients with Cardiac Sarcoidosis. Heart Rhythm 2013. 2013. pp. 1–2.
31. Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest. 2013;143:1085–90. The first retrospective study of atrial arrhythmias in CS.
32. Cain MA, Metzl MD, Patel AR, Addetia K. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014;113(9):1556–60.
33. Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. JAC. 1991;18:937–43.
34. Koplan BA, Soejima K, Baughman K, Epstein LM, Stevenson WG. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. HRTHM. 2006;3:924–9.
35. Jefic D, Joel B, Good E, Morady F, Rosman H, Knight B, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6:189–95.
36. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. HRTHM. 2007;4:1292–9.
37. Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27:217–22.
38. Fleming HA, Bailey SM. Sarcoid heart disease. J R Coll Physicians Lond. 1981;15:245.
39. Uusimaa P, Ylitalo K, Anttonen O, Kerola T, Virtanen V, Pääkkö E, et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace. 2008;10:760–6.
40. Stees CS, Khoo MSC, Lowery CM, Sauer WH. Ventricular tachycardia storm successfully treated with immunosuppression and catheter ablation in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2011;22:210–3.
41. Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Monogr Eur Respir Soc. 2005;32:130.
42. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20:578–83. Wiley Online Library.
43. Hamzeh NY. Management of cardiac sarcoidosis in the United States. Chest. 2012;141:154.
44. Youssef G, Beanlands RSB, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97:2078–87.
45. Yeboah J, Lee C, Sharma OP. Cardiac sarcoidosis. Curr Opin Pulm Med. 2011;17:308–15.
46. Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis. Curr Opin Cardiol. 2012;27:181–9.
47. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999. pp. 736–55.
48. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16:75–86.
49. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58–73.
50. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, Mc Ardle BA, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014. doi:10.1111/jce.12401. This study reports a high incidence of cardiac sarcoidosis in young patients with initially-unexplained AV block.
51. Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of Cardiac Sarcoidosis in Patients Presenting with Monomorphic Ventricular Tachycardia. Pacing and Clinical Electrophysiology. 2013.:n/a–n/a.
52. Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation. 2012;125:e344–6.
53. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythmia Electrophysiol. 2011;4:303–9.
54. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2012;18:733–46.
55. Chia P-L, Subbiah RN, Kuchar D, Walker B. Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy. Heart Lung Circ. 2012;21:42–5.
56. Vasaiwala SC, Finn C, Delpriore J, Leya F, Gagermeier J, Akar JG, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2009;20:473–6.
57. Mohsen A, Panday M, Wetherold S, Jimenez A. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia with high defibrillation threshold requiring subcutaneous shocking coil implantation. Heart Lung Circ. 2012;21:46–9.
58. Aggeli C, Felekos I, Tousoulis D, Gialafos E, Rapti A, Stefanadis C. Myocardial mechanics for the early detection of cardiac sarcoidosis. Int J Cardiol Elsevier Irel Ltd. 2013;168:4820–1.
59. Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106:1021–4.
60. Adamson P, Melton I, O'Donnell J, MacDonald S, Crozier I. Cardiac sarcoidosis: the Christchurch experience. Int Med J. 2014;44:70–6.
61. Judson MA, Thompson BW, Rabin DL, Steimel J, Knattereud GL, Lackland DT, et al. The diagnostic pathway to sarcoidosis. Chest. 2003;123:406–12.
62. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J Elsevier. 2005;150:459–63.
63. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299–302.
64. Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29(1015):e1–3. Describes the by which electroanatomical mapping can guide endomyocardial biopsy to improve diagnostic yield.
65. Pieroni M, Russo Dello A, Marzo F, Pelargonio G, Casella M, Bellocci F, et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy. JAC Am Coll Cardiol Found. 2009;53:681–9.
66. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36.
67. Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging Springer. 2008;35:933–41.
68. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122:1895–901.
69. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996;10:495–510.
70. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JCMG Elsevier Inc. 2013;6:501–11.
71. Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22:234–5.
72. Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241–8.
73. Pandya C, Brunken RC, Tchou P, Schoenhagen P, Culver DA. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J. 2007;29:418–22.
74. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythmia Electrophysiol. 2011;4:43–8.
75. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82.
76. Baughman RP, Ohmichi M, Lower EE. Combination therapy for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:133–7.
77. Baughman RP, Costabel U, du RM B. Treatment of sarcoidosis. Clin Chest Med. 2008;29:533–48. x–x.
78. Baughman RP, Drent M, Kavuru M, JUDSON MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795–802.
79. Mantini N, Williams Jr B, Stewart J, Rubinsztain L, Kacharava A. Cardiac sarcoid: a clinician’s review on how to approach the patient with cardiac sarcoid. Clin Cardiol. 2012;35:410–5.
80. Chiu C-Z, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95:143–6.
81. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140–7.
82. Yodogawa K, Seino Y, Shiomura R, Takahashi K, Tsuboi I, Uetake S, et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol. 2013;62:320–5.
83. Sadek MM, Yung D, Birnie DH, BEANLANDS RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034–41.
84. Kato Y, Morimoto S-I, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133–7.
85. Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2013.
86. Zipse MM, Sauer WH. Electrophysiologic manifestations of cardiac sarcoidosis. Curr Opin Pulm Med. 2013;19:485–92.
87. Writing Committee Members, Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American college of cardiology/american heart association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American association for thoracic surgery and society of thoracic surgeons. Circulation. 2008;117:2820–40.
88. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.
89. Oni AA, Hershberger RE, Norman DJ, Ray J, Hovaguimian H, Cobanoglu AM, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant. 1992;11:367–9.
90. Yager JEE, Hernandez AF, Steenbergen C, Persing B, Russell SD, Milano C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant. 2005;24:1988–90.
91. Milman N, Andersen CB, Mortensen SA, Sander K. Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis. 2008;25:51–9.
92. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transpl Elsevier. 2007;26:714–7.